| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 1987 |
| Founder | Michael Wall |
| Headquarters | , |
Key people | Richard Pops (CEO) |
| Revenue |  US$1.1 billion (2022)[2] |
 US$-20.5 million | |
| US$-158 million (2022) | |
| Total assets | US$1.9 billion |
| Total equity | US$1 billion |
Number of employees | 2,100 |
| Website | www.alkermes.com |
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall.[3] In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc.[4] The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.[1]
- ^ a b Robert Weisman (10 May 2011). "Alkermes to buy Irish drug maker". Boston Globe.
- ^ "Alkermes PLC".
- ^ "Alkermes And Richard Pops — The Evolution Of A Company And Its Leader". LifeScienceLeader.com. 1 May 2019. Retrieved 21 June 2019.
- ^ "Alkermes Reels In Elan's Drug Technology Business". Forbes.com. 9 May 2011. Retrieved 13 October 2011.